Trial Outcomes & Findings for A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT NCT03735121)

NCT ID: NCT03735121

Last Updated: 2025-12-05

Results Overview

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 438 participants
• Primary outcome timeframe: Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)
• Results posted on: 2025-12-05

Participant Flow

A total of 438 participants with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) who were cancer immunotherapy (CIT)-naïve and for whom prior platinum-based therapy failed took part in the study across 23 countries from 27 December 2018 to 22 November 2024. The study is considered "Completed" because all the pre-planned study activities and analyses have been performed.

Study consisted of 2 parts: Part 1 (Dose Finding) & Part 2 (Dose Confirmation). Health care professionals (HCPs) who administered the study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC & atezolizumab IV, the HCPs were asked to complete two questionnaires: 'HCP SC Versus IV Perspective' & 'HCP SC Perspective'. No data other than the HCP's responses to these Questionnaires were collected in this study.

Participant milestones

Measure	Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 milligrams (mg), co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, every 3 weeks (Q3W) on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression (PD), loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 2: Atezolizumab IV 1200 mg Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
Overall Study STARTED	13	15	39	124	247
Overall Study COMPLETED	8	7	13	0	0
Overall Study NOT COMPLETED	5	8	26	124	247

Reasons for withdrawal

Measure	Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 milligrams (mg), co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, every 3 weeks (Q3W) on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression (PD), loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 2: Atezolizumab IV 1200 mg Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
Overall Study Death	3	6	19	97	205
Overall Study Lost to Follow-up	0	0	0	2	3
Overall Study New Therapy	0	1	0	0	0
Overall Study Study Ended by Sponsor	1	0	1	17	28
Overall Study Withdrawal by Subject	1	1	6	8	11

Baseline Characteristics

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Baseline characteristics by cohort

Measure	Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg n=13 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg n=15 Participants Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=39 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 2: Atezolizumab IV 1200 mg n=124 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=247 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Total n=438 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=37 Participants	0 Participants n=37 Participants	0 Participants n=74 Participants	0 Participants n=267 Participants	0 Participants n=272 Participants	0 Participants n=6 Participants
Age, Categorical Between 18 and 65 years	8 Participants n=37 Participants	7 Participants n=37 Participants	19 Participants n=74 Participants	58 Participants n=267 Participants	137 Participants n=272 Participants	229 Participants n=6 Participants
Age, Categorical >=65 years	5 Participants n=37 Participants	8 Participants n=37 Participants	20 Participants n=74 Participants	66 Participants n=267 Participants	110 Participants n=272 Participants	209 Participants n=6 Participants
Sex: Female, Male Female	8 Participants n=37 Participants	6 Participants n=37 Participants	12 Participants n=74 Participants	42 Participants n=267 Participants	72 Participants n=272 Participants	140 Participants n=6 Participants
Sex: Female, Male Male	5 Participants n=37 Participants	9 Participants n=37 Participants	27 Participants n=74 Participants	82 Participants n=267 Participants	175 Participants n=272 Participants	298 Participants n=6 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=37 Participants	0 Participants n=37 Participants	0 Participants n=74 Participants	9 Participants n=267 Participants	15 Participants n=272 Participants	24 Participants n=6 Participants
Race (NIH/OMB) Asian	2 Participants n=37 Participants	2 Participants n=37 Participants	1 Participants n=74 Participants	33 Participants n=267 Participants	47 Participants n=272 Participants	85 Participants n=6 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=37 Participants	0 Participants n=37 Participants	0 Participants n=74 Participants	2 Participants n=267 Participants	1 Participants n=272 Participants	3 Participants n=6 Participants
Race (NIH/OMB) Black or African American	0 Participants n=37 Participants	0 Participants n=37 Participants	0 Participants n=74 Participants	1 Participants n=267 Participants	2 Participants n=272 Participants	3 Participants n=6 Participants
Race (NIH/OMB) White	8 Participants n=37 Participants	11 Participants n=37 Participants	36 Participants n=74 Participants	74 Participants n=267 Participants	174 Participants n=272 Participants	303 Participants n=6 Participants
Race (NIH/OMB) More than one race	0 Participants n=37 Participants	0 Participants n=37 Participants	0 Participants n=74 Participants	5 Participants n=267 Participants	6 Participants n=272 Participants	11 Participants n=6 Participants
Race (NIH/OMB) Unknown or Not Reported	3 Participants n=37 Participants	2 Participants n=37 Participants	2 Participants n=74 Participants	0 Participants n=267 Participants	2 Participants n=272 Participants	9 Participants n=6 Participants
Race/Ethnicity, Customized Hispanic or Latino	1 Participants n=37 Participants	5 Participants n=37 Participants	12 Participants n=74 Participants	36 Participants n=267 Participants	61 Participants n=272 Participants	115 Participants n=6 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	9 Participants n=37 Participants	7 Participants n=37 Participants	25 Participants n=74 Participants	88 Participants n=267 Participants	185 Participants n=272 Participants	314 Participants n=6 Participants
Race/Ethnicity, Customized Not Stated	3 Participants n=37 Participants	3 Participants n=37 Participants	2 Participants n=74 Participants	0 Participants n=267 Participants	0 Participants n=272 Participants	8 Participants n=6 Participants
Race/Ethnicity, Customized Unknown	0 Participants n=37 Participants	0 Participants n=37 Participants	0 Participants n=74 Participants	0 Participants n=267 Participants	1 Participants n=272 Participants	1 Participants n=6 Participants

PRIMARY outcome

Timeframe: Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)

Population: Pharmacokinetic (PK)-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=15 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=35 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1	121 micrograms per milliliter (μg/mL) Geometric Coefficient of Variation 42.8	77.5 micrograms per milliliter (μg/mL) Geometric Coefficient of Variation 51.4	78.3 micrograms per milliliter (μg/mL) Geometric Coefficient of Variation 88.6

PRIMARY outcome

Timeframe: Predose on Day 1 of Cycle 2 (Cycle length =21 days)

Population: Per Protocol PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms who did not have protocol deviations that could affect Cycle 1 observed Ctrough results.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=97 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=205 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1	85.4 μg/mL Geometric Coefficient of Variation 34.1	89.4 μg/mL Geometric Coefficient of Variation 127.1	—

PRIMARY outcome

Timeframe: From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=122 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=246 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1	3327.9 micrograms day per mL (μg*day/mL) Geometric Coefficient of Variation 19.4	2907.1 micrograms day per mL (μg*day/mL) Geometric Coefficient of Variation 35.9	—

SECONDARY outcome

Timeframe: Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=14 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=30 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab	251 μg/mL Geometric Coefficient of Variation 40.9	129 μg/mL Geometric Coefficient of Variation 42.5	181 μg/mL Geometric Coefficient of Variation 38.3

SECONDARY outcome

Timeframe: Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=14 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=30 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab	3.02 days Interval 2.93 to 7.8	3.45 days Interval 3.0 to 8.95	3.92 days Interval 2.99 to 7.11

SECONDARY outcome

Timeframe: Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2)

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=14 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=30 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab	3870 μg*day/mL Geometric Coefficient of Variation 38.6	1410 μg*day/mL Geometric Coefficient of Variation 41.8	2820 μg*day/mL Geometric Coefficient of Variation 38.6

SECONDARY outcome

Timeframe: Cohort 1: Predose: D1 & postdose: D1, 3, 8 of C1; Cohort 2: Pre & postdose: D1 of C1, 3 & postdose: D3, 8 of C1, Predose: D1 of C2; Cohort 3: Pre & postdose: D1 of C1, 2 & postdose: D3, 8 of C1, D2, 4 & 9 of C2 & pre dose: D1 of C3

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint.

Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2. Day=D; Cycle=C.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=15 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=39 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 1, Day 1: Pre-dose	NA μg/mL Geometric Coefficient of Variation NA The data was not evaluable as all the samples were below lower limit of quantification (BLLQ).	NA μg/mL Geometric Coefficient of Variation NA The data was not evaluable as all the samples were BLLQ.	NA μg/mL Geometric Coefficient of Variation NA The data was not evaluable as all the samples were BLLQ.
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 1, Day 1: Post-dose	116 μg/mL Geometric Coefficient of Variation 57.8	61.7 μg/mL Geometric Coefficient of Variation 70.9	108 μg/mL Geometric Coefficient of Variation 57.6
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 1, Day 3: Post-dose	247 μg/mL Geometric Coefficient of Variation 40.5	123 μg/mL Geometric Coefficient of Variation 44.3	166 μg/mL Geometric Coefficient of Variation 45.7
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 1, Day 8: Post-dose	230 μg/mL Geometric Coefficient of Variation 36.6	110 μg/mL Geometric Coefficient of Variation 45.0	162 μg/mL Geometric Coefficient of Variation 43.5
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 2, Day 1: Pre-dose	—	77.5 μg/mL Geometric Coefficient of Variation 51.4	78.3 μg/mL Geometric Coefficient of Variation 88.6
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 2, Day 1: Post-dose	—	—	87.7 μg/mL Geometric Coefficient of Variation 64.7
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 2, Day 2: Post-dose	—	—	183 μg/mL Geometric Coefficient of Variation 46.1
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 2, Day 4: Post-dose	—	—	245 μg/mL Geometric Coefficient of Variation 42.0
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 2, Day 9: Post-dose	—	—	225 μg/mL Geometric Coefficient of Variation 37.2
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 3, Day 1: Pre-dose	—	104 μg/mL Geometric Coefficient of Variation 47.8	123 μg/mL Geometric Coefficient of Variation 57.2
Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration Cycle 3, Day 1: Post-dose	—	189 μg/mL Geometric Coefficient of Variation NA Since only 1 participant was analysed the geometric coefficient of variation could not be calculated.	—

SECONDARY outcome

Timeframe: From initiation of study treatment up to approximately 69 months

Population: Safety-evaluable population included all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received.

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=15 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=39 Participants Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 1: Percentage of Participants With Adverse Events (AEs)	100 percentage of participants	86.7 percentage of participants	84.6 percentage of participants

SECONDARY outcome

Timeframe: From initiation of study treatment up to approximately 44.7 months

Population: Safety-evaluable population included all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received.

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, V5.0. Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=124 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=247 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of Participants With AEs	85.5 percentage of participants	89.9 percentage of participants	—

SECONDARY outcome

Timeframe: Cycle 1 (Cycle length=21 days)

Population: PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms with at least one post-baseline PK sample. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=122 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=246 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1	88.7 μg/mL Geometric Coefficient of Variation 26.2	97.2 μg/mL Geometric Coefficient of Variation 42.3	—

SECONDARY outcome

Timeframe: Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis.

1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=122 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=246 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Model Predicted Ctrough at Steady State (Ctrough,ss) of Atezolizumab	179 μg/mL Geometric Coefficient of Variation 38.8	205 μg/mL Geometric Coefficient of Variation 58.1	—

SECONDARY outcome

Timeframe: Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)

Population: PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis.

1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=122 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=246 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab	6107 ug*day/mL Geometric Coefficient of Variation 27.3	6163 ug*day/mL Geometric Coefficient of Variation 46.7	—

SECONDARY outcome

Timeframe: Up to approximately 25 months

Population: Response-evaluable population included all participants with measurable disease at baseline.

ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1). CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to < 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD in the absence of CR. Percentage of participants who achieved confirmed objective response (CR or PR) have been reported. Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=124 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=245 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Objective Response Rate (ORR)	10.5 percentage of participants Interval 5.7 to 17.3	11.0 percentage of participants Interval 7.4 to 15.6	—

SECONDARY outcome

Timeframe: Up to approximately 25 months

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment.

PFS was defined as the time from study start to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. PFS was analyzed using the Kaplan-Meier method.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=124 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=247 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Progression-free Survival (PFS)	2.9 months Interval 1.8 to 4.2	2.8 months Interval 2.7 to 4.1	—

SECONDARY outcome

Timeframe: Up to approximately 44.7 months

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment.

OS was defined as the time from the date of study randomization to the date of death from any cause.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=124 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=247 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Overall Survival (OS)	10.1 months Interval 7.5 to 12.3	10.9 months Interval 8.5 to 14.4	—

SECONDARY outcome

Timeframe: Up to approximately 25 months

Population: DOR-evaluable population included all participants with a measurable disease at baseline and a post-baseline confirmed objective response (CR or PR).

DOR was defined as the time from first occurrence of a documented confirmed objective response (CR or PR) to PD as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to < 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SODs must also demonstrate an absolute increase of ≥ 5 mm.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=13 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=27 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Duration of Response (DOR)	11.2 months Interval 4.2 to The upper limit of the 95% confidence interval (CI) was not estimable due to an insufficient number of participants with events.	15.1 months Interval 5.6 to The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events.	—

SECONDARY outcome

Timeframe: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

EORTC IL57 questionnaire has 10 items and covers 3 scales: physical functioning (PF), role functioning (RF) & global health status/quality of life (GHS/QoL) & 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks & short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work & pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health & QoL in previous week. Questions are answered on a 4-point Likert scale (where 1="Not at all" to 4="Very much") for physical and role functioning & a 7-point scale (where 1="Very poor" to 7="Excellent") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=117 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=243 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Baseline	74.53 score on a scale Standard Deviation 20.37	72.15 score on a scale Standard Deviation 21.94	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 2	-6.23 score on a scale Standard Deviation 19.17	-4.23 score on a scale Standard Deviation 17.01	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 3	-4.55 score on a scale Standard Deviation 19.04	-4.99 score on a scale Standard Deviation 17.63	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 4	-5.75 score on a scale Standard Deviation 22.04	-4.47 score on a scale Standard Deviation 20.86	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 5	-1.46 score on a scale Standard Deviation 21.40	-2.14 score on a scale Standard Deviation 20.05	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 6	-2.76 score on a scale Standard Deviation 25.68	-0.67 score on a scale Standard Deviation 20.09	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 8	-0.14 score on a scale Standard Deviation 19.24	-0.42 score on a scale Standard Deviation 19.76	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 10	-1.46 score on a scale Standard Deviation 22.39	0.82 score on a scale Standard Deviation 20.96	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 12	0.95 score on a scale Standard Deviation 22.64	1.14 score on a scale Standard Deviation 20.43	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 14	0.67 score on a scale Standard Deviation 19.37	1.11 score on a scale Standard Deviation 18.82	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 16	-2.14 score on a scale Standard Deviation 23.38	2.26 score on a scale Standard Deviation 19.30	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 18	-0.87 score on a scale Standard Deviation 19.10	0.67 score on a scale Standard Deviation 19.30	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 20	-1.59 score on a scale Standard Deviation 22.30	-0.15 score on a scale Standard Deviation 19.53	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 22	-2.22 score on a scale Standard Deviation 23.54	-1.67 score on a scale Standard Deviation 23.66	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 24	-0.83 score on a scale Standard Deviation 22.69	-1.76 score on a scale Standard Deviation 20.97	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 26	0.83 score on a scale Standard Deviation 17.36	-1.94 score on a scale Standard Deviation 23.61	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 28	2.38 score on a scale Standard Deviation 14.70	0.51 score on a scale Standard Deviation 19.46	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 30	2.05 score on a scale Standard Deviation 16.42	0.95 score on a scale Standard Deviation 18.89	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 32	-6.67 score on a scale Standard Deviation 21.27	0.61 score on a scale Standard Deviation 22.34	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 34	-2.42 score on a scale Standard Deviation 16.40	3.00 score on a scale Standard Deviation 26.62	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 36	0.61 score on a scale Standard Deviation 17.24	6.00 score on a scale Standard Deviation 23.59	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 38	3.64 score on a scale Standard Deviation 17.22	4.07 score on a scale Standard Deviation 24.96	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 40	0.00 score on a scale Standard Deviation 25.65	1.11 score on a scale Standard Deviation 23.79	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 42	1.67 score on a scale Standard Deviation 19.76	2.96 score on a scale Standard Deviation 21.36	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 44	5.83 score on a scale Standard Deviation 12.57	5.00 score on a scale Standard Deviation 21.15	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 46	5.83 score on a scale Standard Deviation 16.88	5.88 score on a scale Standard Deviation 26.34	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 48	8.57 score on a scale Standard Deviation 10.69	8.10 score on a scale Standard Deviation 24.13	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 50	4.76 score on a scale Standard Deviation 14.76	9.09 score on a scale Standard Deviation 29.25	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 52	12.22 score on a scale Standard Deviation 12.94	5.33 score on a scale Standard Deviation 24.30	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 54	11.11 score on a scale Standard Deviation 10.18	6.67 score on a scale Standard Deviation 29.81	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 56	10.00 score on a scale Standard Deviation 4.71	8.89 score on a scale Standard Deviation 13.88	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 58	6.67 score on a scale Standard Deviation NA Standard deviation (SD) was not estimable since only 1 participant was evaluated.	3.33 score on a scale Standard Deviation 14.14	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 60	20.00 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	13.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 62	13.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	13.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Day 1 Cycle 64	—	13.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score Change at Treatment Discontinuation Visit	-19.01 score on a scale Standard Deviation 28.26	-15.68 score on a scale Standard Deviation 25.67	—

SECONDARY outcome

Timeframe: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF & GHS/QoL & 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks & short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work & pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health & QoL in previous week. Questions are answered on a 4-point Likert scale (where 1="Not at all" to 4="Very much") for physical and role functioning & a 7-point scale (where 1="Very poor" to 7="Excellent") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=117 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=242 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Baseline	74.93 score on a scale Standard Deviation 25.67	74.86 score on a scale Standard Deviation 27.51	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 2	0.31 score on a scale Standard Deviation 29.46	-4.36 score on a scale Standard Deviation 24.48	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 3	-3.29 score on a scale Standard Deviation 27.51	-4.67 score on a scale Standard Deviation 25.83	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 4	-0.83 score on a scale Standard Deviation 26.90	-6.59 score on a scale Standard Deviation 28.63	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 5	2.34 score on a scale Standard Deviation 31.13	-5.22 score on a scale Standard Deviation 30.27	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 6	0.00 score on a scale Standard Deviation 32.14	-5.74 score on a scale Standard Deviation 29.39	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 8	4.96 score on a scale Standard Deviation 29.47	-1.95 score on a scale Standard Deviation 25.50	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 10	1.63 score on a scale Standard Deviation 29.06	-0.82 score on a scale Standard Deviation 24.71	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 12	4.29 score on a scale Standard Deviation 29.80	-2.66 score on a scale Standard Deviation 30.20	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 14	6.11 score on a scale Standard Deviation 22.09	-3.61 score on a scale Standard Deviation 30.24	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 16	-0.60 score on a scale Standard Deviation 29.91	-1.26 score on a scale Standard Deviation 27.12	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 18	0.72 score on a scale Standard Deviation 21.60	-2.00 score on a scale Standard Deviation 27.90	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 20	7.94 score on a scale Standard Deviation 30.10	-2.65 score on a scale Standard Deviation 27.83	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 22	6.48 score on a scale Standard Deviation 28.66	-5.09 score on a scale Standard Deviation 34.23	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 24	3.13 score on a scale Standard Deviation 24.51	-4.41 score on a scale Standard Deviation 29.39	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 26	4.17 score on a scale Standard Deviation 36.77	0.54 score on a scale Standard Deviation 27.38	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 28	7.14 score on a scale Standard Deviation 16.94	5.07 score on a scale Standard Deviation 29.91	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 30	-2.56 score on a scale Standard Deviation 20.24	3.17 score on a scale Standard Deviation 31.01	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 32	-6.94 score on a scale Standard Deviation 19.41	-0.76 score on a scale Standard Deviation 31.49	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 36	-3.03 score on a scale Standard Deviation 17.98	1.67 score on a scale Standard Deviation 31.48	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 38	4.55 score on a scale Standard Deviation 16.82	5.56 score on a scale Standard Deviation 26.20	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 40	1.52 score on a scale Standard Deviation 24.10	1.85 score on a scale Standard Deviation 28.52	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 42	-6.25 score on a scale Standard Deviation 23.46	3.70 score on a scale Standard Deviation 32.11	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 44	-2.08 score on a scale Standard Deviation 16.52	7.29 score on a scale Standard Deviation 31.60	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 46	0.00 score on a scale Standard Deviation 23.57	4.90 score on a scale Standard Deviation 32.68	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 48	2.38 score on a scale Standard Deviation 20.25	8.33 score on a scale Standard Deviation 31.86	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 50	2.38 score on a scale Standard Deviation 20.25	13.64 score on a scale Standard Deviation 36.38	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 52	2.78 score on a scale Standard Deviation 28.71	1.67 score on a scale Standard Deviation 24.15	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 54	-11.11 score on a scale Standard Deviation 34.69	2.08 score on a scale Standard Deviation 36.12	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 56	0.00 score on a scale Standard Deviation 23.57	-5.56 score on a scale Standard Deviation 19.25	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 58	-33.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	0.00 score on a scale Standard Deviation 23.57	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 60	16.67 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	16.67 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 62	16.67 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	16.67 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 64	—	16.67 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Treatment Discontinuation Visit	-20.27 score on a scale Standard Deviation 33.70	-21.14 score on a scale Standard Deviation 34.80	—
Part 2: Change From Baseline in EORTC IL57 Role Functioning Score Change at Day 1 Cycle 34	-6.06 score on a scale Standard Deviation 22.70	0.00 score on a scale Standard Deviation 34.20	—

SECONDARY outcome

Timeframe: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF & GHS/QoL & 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks & short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work & pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health & QoL in previous week. Questions are answered on a 4-point Likert scale (where 1="Not at all" to 4="Very much") for physical and role functioning & a 7-point scale (where 1="Very poor" to 7="Excellent") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=117 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=242 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Baseline	66.52 score on a scale Standard Deviation 17.68	63.50 score on a scale Standard Deviation 22.00	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 2	-3.54 score on a scale Standard Deviation 21.33	-2.48 score on a scale Standard Deviation 21.77	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 3	-2.91 score on a scale Standard Deviation 20.92	-1.83 score on a scale Standard Deviation 23.04	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 4	-2.71 score on a scale Standard Deviation 19.61	-2.25 score on a scale Standard Deviation 22.21	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 5	0.65 score on a scale Standard Deviation 19.26	-1.43 score on a scale Standard Deviation 25.35	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 6	-0.14 score on a scale Standard Deviation 21.99	0.14 score on a scale Standard Deviation 22.94	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 8	3.01 score on a scale Standard Deviation 18.26	1.86 score on a scale Standard Deviation 22.74	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 10	5.28 score on a scale Standard Deviation 19.87	0.72 score on a scale Standard Deviation 23.17	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 12	6.19 score on a scale Standard Deviation 18.45	-2.78 score on a scale Standard Deviation 18.56	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 14	7.50 score on a scale Standard Deviation 17.42	1.94 score on a scale Standard Deviation 19.67	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 28	1.79 score on a scale Standard Deviation 16.72	1.81 score on a scale Standard Deviation 21.17	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 30	5.77 score on a scale Standard Deviation 16.45	3.17 score on a scale Standard Deviation 21.81	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 32	0.00 score on a scale Standard Deviation 18.46	0.38 score on a scale Standard Deviation 17.91	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 34	0.00 score on a scale Standard Deviation 20.07	2.50 score on a scale Standard Deviation 19.70	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 36	-1.52 score on a scale Standard Deviation 15.73	1.67 score on a scale Standard Deviation 20.52	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 38	2.27 score on a scale Standard Deviation 21.11	3.70 score on a scale Standard Deviation 20.66	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 40	5.30 score on a scale Standard Deviation 21.50	1.39 score on a scale Standard Deviation 19.85	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 42	0.00 score on a scale Standard Deviation 17.25	2.31 score on a scale Standard Deviation 20.37	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 44	2.08 score on a scale Standard Deviation 18.23	3.65 score on a scale Standard Deviation 19.95	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 16	6.55 score on a scale Standard Deviation 17.77	1.73 score on a scale Standard Deviation 18.52	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 46	2.08 score on a scale Standard Deviation 25.88	2.45 score on a scale Standard Deviation 21.60	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 48	7.14 score on a scale Standard Deviation 15.54	4.17 score on a scale Standard Deviation 20.35	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 50	-2.38 score on a scale Standard Deviation 17.16	3.03 score on a scale Standard Deviation 21.82	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 52	8.33 score on a scale Standard Deviation 12.91	-3.33 score on a scale Standard Deviation 16.76	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 54	-2.78 score on a scale Standard Deviation 12.73	0.00 score on a scale Standard Deviation 22.27	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 56	4.17 score on a scale Standard Deviation 5.89	2.78 score on a scale Standard Deviation 4.81	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 58	0.00 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	0.00 score on a scale Standard Deviation 0.00	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 60	8.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	0.00 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 62	-8.33 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	0.00 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 64	—	0.00 score on a scale Standard Deviation NA SD was not estimable since only 1 participant was evaluated.	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Treatment Discontinuation Visit	-14.53 score on a scale Standard Deviation 26.28	-13.37 score on a scale Standard Deviation 25.42	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 18	4.71 score on a scale Standard Deviation 19.11	0.67 score on a scale Standard Deviation 17.56	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 20	9.52 score on a scale Standard Deviation 16.73	-0.95 score on a scale Standard Deviation 18.52	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 22	5.56 score on a scale Standard Deviation 21.20	0.00 score on a scale Standard Deviation 19.92	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 24	7.29 score on a scale Standard Deviation 28.20	-2.70 score on a scale Standard Deviation 18.99	—
Part 2: Change From Baseline in EORTC IL57 Global Health Status Score Change at Day 1 Cycle 26	1.56 score on a scale Standard Deviation 24.95	-2.15 score on a scale Standard Deviation 21.51	—

SECONDARY outcome

Timeframe: Day 1 Cycle 3 or Treatment Discontinuation Visit (if treatment discontinued at any visit before Cycle 3) (Cycle length = 21 days)

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

Modified SWT scale of the CTSQ consisted of seven items that measured seven domains related to satisfaction with cancer therapy. These include worthwhile, difficulty, benefits, feelings about side effects, form of therapy, overall satisfaction, and if participants would choose the therapy taking everything into consideration. Each domain is rated on a 5-point scale, with 1 representing the worst response and 5 representing the best response, except in the case of one reverse-scored item. Mean of the items were linearly transformed to obtain scores from 0-100, where 100 was the best possible score. Higher scores indicate higher satisfaction. Here, data for 'overall satisfaction' domain has been presented.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=98 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=191 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ) Day 1 Cycle 3	77.29 score on a scale Standard Deviation 16.08	75.56 score on a scale Standard Deviation 18.61	—
Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ) Treatment Discontinuation Visit	50.67 score on a scale Standard Deviation 19.90	61.21 score on a scale Standard Deviation 19.81	—

SECONDARY outcome

Timeframe: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64 (Cycle length = 21 days)

Population: FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

The overall patient-reported AE burden was assessed using a single item from the EORTC IL57 questionnaire i.e "To what extent have you been troubled with side-effects from your treatment?" The questions were answered on a 4-point Likert scale, where 1="Not at all" to 4="Very much". Higher scores indicated greater AE burden. Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=113 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=238 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 34 - Not at all	72.7 percentage of participants	65.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 32 - Quite a bit	8.3 percentage of participants	4.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 34 - A little	27.3 percentage of participants	35.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 36 - Not at all	63.6 percentage of participants	65.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 36 - A little	36.4 percentage of participants	35.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 38 - Not at all	72.7 percentage of participants	61.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 38 - A little	27.3 percentage of participants	33.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 40 - Quite a bit	0 percentage of participants	5.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 44 - Not at all	75.0 percentage of participants	68.8 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 44 - A little	25.0 percentage of participants	31.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 46 - Not at all	87.5 percentage of participants	76.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 46 - A little	0 percentage of participants	23.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 46 - Quite a bit	12.5 percentage of participants	0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 48 - Not at all	100 percentage of participants	71.4 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 48 - A little	0 percentage of participants	28.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 50 - Not at all	100 percentage of participants	63.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 50 - A little	0 percentage of participants	36.4 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 52 - Not at all	100 percentage of participants	60.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 52 - A little	0 percentage of participants	40.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 54 - Not at all	100 percentage of participants	50.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 54 - A little	0 percentage of participants	50.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 56 - Not at all	100 percentage of participants	0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 56 - A little	0 percentage of participants	100 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 58 - Not at all	100 percentage of participants	50.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 58 - A little	0 percentage of participants	50.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 60 - A little	0 percentage of participants	100 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 62 - Not at all	100 percentage of participants	0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 64 - A little	—	100 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 32 - A little	41.7 percentage of participants	36.4 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 38 - Quite a bit	0 percentage of participants	5.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 40 - Not at all	72.7 percentage of participants	55.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 40 - A little	27.3 percentage of participants	38.9 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 42 - Not at all	75.0 percentage of participants	66.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 42 - A little	25.0 percentage of participants	33.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 60 - Not at all	100 percentage of participants	0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 62 - A little	0 percentage of participants	100 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 18 - A little	30.4 percentage of participants	36.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 18 - Quite a bit	0 percentage of participants	6.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 20 - Not at all	71.4 percentage of participants	59.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 20 - A little	28.6 percentage of participants	31.8 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 20 - Quite a bit	0 percentage of participants	9.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 22 - Not at all	55.6 percentage of participants	52.8 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 22 - A little	38.9 percentage of participants	36.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 22 - Quite a bit	5.6 percentage of participants	11.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 24 - Not at all	75.0 percentage of participants	55.9 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 24 - A little	25.0 percentage of participants	38.2 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 24 - Quite a bit	0 percentage of participants	5.9 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 26 - Not at all	73.3 percentage of participants	51.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 26 - A little	26.7 percentage of participants	41.9 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 26 - Quite a bit	0 percentage of participants	6.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 28 - Not at all	64.3 percentage of participants	56.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 28 - A little	35.7 percentage of participants	39.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 28 - Quite a bit	0 percentage of participants	4.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 30 - Not at all	69.2 percentage of participants	70.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 30 - A little	30.8 percentage of participants	25.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 30 - Quite a bit	0 percentage of participants	5.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 32 - Not at all	50.0 percentage of participants	59.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 3 - Not at all	43.2 percentage of participants	46.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 3 - A little	45.5 percentage of participants	41.8 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Baseline - Not at all	49.6 percentage of participants	56.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Baseline - A little	36.3 percentage of participants	28.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Baseline - Quite a bit	8.0 percentage of participants	10.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Baseline - Very much	6.2 percentage of participants	4.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 2 - Not at all	47.2 percentage of participants	49.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 2 - A little	39.8 percentage of participants	35.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 2 - Quite a bit	9.3 percentage of participants	12.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 2 - Very much	3.7 percentage of participants	2.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 3 - Quite a bit	10.2 percentage of participants	8.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 3 - Very much	1.1 percentage of participants	2.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 4 - Not at all	48.8 percentage of participants	46.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 4 - A little	36.6 percentage of participants	36.1 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 4 - Quite a bit	14.6 percentage of participants	15.4 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 4 - Very much	0 percentage of participants	1.8 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 5 - Not at all	56.3 percentage of participants	55.9 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 5 - A little	35.9 percentage of participants	36.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 5 - Quite a bit	7.8 percentage of participants	5.9 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 6 - Not at all	54.2 percentage of participants	49.2 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 6 - A little	37.3 percentage of participants	40.2 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 6 - Quite a bit	8.5 percentage of participants	8.2 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 6 - Very much	0 percentage of participants	2.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 8 - Not at all	62.5 percentage of participants	58.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 8 - A little	33.3 percentage of participants	37.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 8 - Quite a bit	4.2 percentage of participants	4.2 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 10 - Not at all	66.7 percentage of participants	54.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 10 - A little	28.6 percentage of participants	44.4 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 10 - Quite a bit	4.8 percentage of participants	1.2 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 12 - Not at all	63.9 percentage of participants	50.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 12 - A little	30.6 percentage of participants	45.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 12 - Quite a bit	5.6 percentage of participants	4.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 14 - Not at all	61.3 percentage of participants	53.3 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 14 - A little	25.8 percentage of participants	45.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 14 - Quite a bit	12.9 percentage of participants	1.7 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 16 - Not at all	60.7 percentage of participants	56.6 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 16 - A little	28.6 percentage of participants	35.8 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 16 - Quite a bit	10.7 percentage of participants	7.5 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 18 - Not at all	69.6 percentage of participants	58.0 percentage of participants	—
Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 Day 1 Cycle 5 - Very much	0 percentage of participants	2.2 percentage of participants	—

SECONDARY outcome

Timeframe: From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)

Population: Safety-evaluable population included all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. Overall number analyzed is the number of participants with data available for analysis.

The percentage of ADA-positive participants after atezolizumab administration was reported. Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=112 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=228 Participants Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration	14.3 percentage of participants	20.6 percentage of participants	—

SECONDARY outcome

Timeframe: From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)

Population: Safety-evaluable population included all participants who received at least one dose of atezolizumab SC formulated with rHuPH20. Overall number analyzed is the number of participants with data available for analysis.

The percentage of ADA-positive participants after atezolizumab SC formulated with rHuPH20 administration was reported. Participants who received atezolizumab SC formulated with rHuPH20 were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following rHuPH20 exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 t.u. greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=228 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration	5.7 percentage of participants	—	—

SECONDARY outcome

Timeframe: After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)

Population: Overall number analyzed included HCPs who completed Question 2 of the questionnaire.

The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Which formulation of atezolizumab (SC or IV) do you think is more convenient for you? Responses to this question are reported in the data table. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'first participant in [FPI]' date to 'last participant last visit [LPLV]' for Part 2).

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=50 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire Atezolizumab SC is a little more convenient	16.0 percentage of HCPs	—	—
Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire Atezolizumab SC is much more convenient	24.0 percentage of HCPs	—	—
Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire Both formulations are equally convenient	26.0 percentage of HCPs	—	—
Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire Atezolizumab IV is a little more convenient	12.0 percentage of HCPs	—	—
Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire Atezolizumab IV is much more convenient	22.0 percentage of HCPs	—	—

SECONDARY outcome

Timeframe: After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)

Population: Overall number analyzed included HCPs who completed Question 3 of the questionnaire.

The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: If used in routine practice, do you think administering atezolizumab SC could save staff time compared to atezolizumab IV? The responses to this question could be Yes; No; Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=50 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire Yes	74.0 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire Unsure	14.0 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire No	12.0 percentage of HCPs	—	—

SECONDARY outcome

Timeframe: After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)

Population: Overall number analyzed included HCPs who completed Question 4 of the questionnaire.

The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, were you more satisfied with atezolizumab SC or atezolizumab IV? The responses included: More satisfied with atezolizumab SC; Equally satisfied with both formulations; More satisfied with atezolizumab IV. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=50 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire More satisfied with atezolizumab IV	30.0 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire More satisfied with atezolizumab SC	32.0 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire Equally satisfied with both formulations	38.0 percentage of HCPs	—	—

SECONDARY outcome

Timeframe: After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)

Population: Overall number analyzed included HCPs who completed Question 2 of the questionnaire.

The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Do you think atezolizumab SC is convenient? The responses to this question could be: Yes; No; and Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=84 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire Yes	78.6 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire Unsure	14.3 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire No	7.1 percentage of HCPs	—	—

SECONDARY outcome

Timeframe: After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)

Population: Overall number analyzed included HCPs who completed Question 3 of the questionnaire.

The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: Overall, how easy did you find atezolizumab SC administration? The responses to this question could be: Very easy; Fairly easy; Not at all easy. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=84 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire Fairly easy	34.5 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire Very easy	54.8 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire Not at all easy	10.7 percentage of HCPs	—	—

SECONDARY outcome

Timeframe: After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)

Population: Overall number analyzed included HCPs who completed Question 4 of the questionnaire.

The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, how satisfied were you with atezolizumab SC? The responses to this question could be: Very satisfied; Satisfied; Dissatisfied; Very dissatisfied. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.

Outcome measures

Measure	Part 2: Atezolizumab IV 1200 mg n=84 Participants Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire Dissatisfied	13.1 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire Very dissatisfied	2.4 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire Very satisfied	34.5 percentage of HCPs	—	—
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire Satisfied	50.0 percentage of HCPs	—	—

Adverse Events

Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg

Serious events: 2 serious events

Other events: 13 other events

Deaths: 4 deaths

Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg

Serious events: 4 serious events

Other events: 12 other events

Deaths: 6 deaths

Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg

Serious events: 8 serious events

Other events: 31 other events

Deaths: 19 deaths

Part 2: Atezolizumab IV 1200 mg

Serious events: 35 serious events

Other events: 91 other events

Deaths: 97 deaths

Part 2: Atezolizumab SC 1875 mg

Serious events: 50 serious events

Other events: 204 other events

Deaths: 206 deaths

Serious adverse events

Measure	Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg n=13 participants at risk Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg n=15 participants at risk Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=39 participants at risk Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 2: Atezolizumab IV 1200 mg n=124 participants at risk Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=247 participants at risk Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
Blood and lymphatic system disorders Anaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Blood and lymphatic system disorders Splenic infarction	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Acute coronary syndrome	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Arrhythmia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Autoimmune myocarditis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Cardiac arrest	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Cardiac failure	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Cardiac failure congestive	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Myocardial infarction	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Eye disorders Cataract	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Abdominal pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Colitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Constipation	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Diarrhoea	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Dysphagia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Enterocolitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Intestinal perforation	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Nausea	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Oesophageal pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Oesophageal stenosis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Vomiting	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Chest pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Death	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Pyrexia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Hepatobiliary disorders Immune-mediated hepatitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Bronchitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations COVID-19	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 4/124 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations COVID-19 pneumonia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Enteritis infectious	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Gastroenteritis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Influenza	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Lung abscess	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pneumocystis jirovecii pneumonia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pneumonia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 8/247 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pneumonia aspiration	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pneumonia bacterial	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pulmonary sepsis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pyelonephritis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pyelonephritis acute	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Respiratory tract infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Sepsis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Tracheobronchitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Upper respiratory tract infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Urinary tract infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Vascular device infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Ischaemic stroke	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Fall	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Head injury	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Alanine aminotransferase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Aspartate aminotransferase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood sodium decreased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Dehydration	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Balance disorder	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Cerebrovascular accident	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Epilepsy	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Transient ischaemic attack	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Renal and urinary disorders Nephropathy	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Renal and urinary disorders Renal failure	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Renal and urinary disorders Tubulointerstitial nephritis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Drug reaction with eosinophilia and systemic symptoms	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Toxic epidermal necrolysis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Vascular disorders Aortic aneurysm	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Vascular disorders Orthostatic hypotension	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Vascular disorders Peripheral arterial occlusive disease	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.

Other adverse events

Measure	Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg n=13 participants at risk Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg n=15 participants at risk Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg n=39 participants at risk Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.	Part 2: Atezolizumab IV 1200 mg n=124 participants at risk Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.	Part 2: Atezolizumab SC 1875 mg n=247 participants at risk Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
Blood and lymphatic system disorders Anaemia	23.1% 3/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	33.3% 5/15 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	33.3% 13/39 • Number of events 16 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	16.9% 21/124 • Number of events 30 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	19.0% 47/247 • Number of events 54 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Blood and lymphatic system disorders Leukocytosis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 8/247 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Blood and lymphatic system disorders Neutropenia	7.7% 1/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.6% 9/247 • Number of events 18 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Supraventricular tachycardia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Cardiac disorders Tachycardia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Endocrine disorders Hyperthyroidism	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.8% 7/247 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Endocrine disorders Hypothyroidism	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.5% 21/247 • Number of events 25 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Eye disorders Periorbital oedema	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Abdominal pain	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.9% 12/247 • Number of events 12 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Anal haemorrhage	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Constipation	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.3% 9/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.9% 17/247 • Number of events 17 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Diarrhoea	30.8% 4/13 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.5% 21/247 • Number of events 27 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Dry mouth	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Dyspepsia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Flatulence	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Nausea	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.0% 3/15 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	23.1% 9/39 • Number of events 12 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 4/124 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.1% 15/247 • Number of events 16 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Stomatitis	7.7% 1/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Gastrointestinal disorders Vomiting	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.8% 7/247 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Asthenia	38.5% 5/13 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.0% 3/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	17.9% 7/39 • Number of events 12 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.3% 9/124 • Number of events 11 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 19/247 • Number of events 19 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Chest pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.3% 9/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.5% 11/247 • Number of events 14 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Chills	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Fatigue	7.7% 1/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.0% 3/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	28.2% 11/39 • Number of events 14 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.9% 16/124 • Number of events 20 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.6% 31/247 • Number of events 33 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Gait disturbance	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Injection site erythema	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Injection site inflammation	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Injection site reaction	23.1% 3/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Mucosal inflammation	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Oedema	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Oedema peripheral	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Pyrexia	23.1% 3/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.9% 12/247 • Number of events 16 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
General disorders Xerosis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Asymptomatic bacteriuria	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Bronchitis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations COVID-19	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.1% 10/124 • Number of events 11 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 19/247 • Number of events 19 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Conjunctivitis bacterial	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Folliculitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Fungal infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Furuncle	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Laryngitis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Nasopharyngitis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pharyngitis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Pneumonia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.3% 13/247 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Respiratory tract infection	7.7% 1/13 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Sinusitis	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Upper respiratory tract infection	15.4% 2/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.8% 7/247 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Urinary tract infection	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.5% 8/124 • Number of events 11 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.5% 11/247 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Vestibular neuronitis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Infections and infestations Viral infection	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Injection related reaction	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Lack of injection site rotation	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Injury, poisoning and procedural complications Procedural pain	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Alanine aminotransferase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.8% 5/39 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.1% 10/124 • Number of events 12 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	9.7% 24/247 • Number of events 25 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Amylase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.8% 5/39 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Aspartate aminotransferase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.5% 13/124 • Number of events 14 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	9.3% 23/247 • Number of events 28 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood albumin decreased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood alkaline phosphatase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.1% 20/247 • Number of events 21 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood bilirubin increased	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood cholesterol increased	7.7% 1/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.0% 3/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.8% 5/39 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood creatinine increased	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 6/247 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood glucose increased	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood lactate dehydrogenase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.9% 12/247 • Number of events 16 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood magnesium decreased	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood sodium decreased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood thyroid stimulating hormone increased	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.8% 7/247 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Blood triglycerides increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Gamma-glutamyltransferase increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 4/124 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.8% 7/247 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Haemoglobin decreased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Lipase increased	7.7% 1/13 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.8% 5/39 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Neutrophil count increased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Platelet count decreased	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Investigations Weight decreased	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.1% 15/247 • Number of events 18 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Decreased appetite	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.0% 3/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.5% 8/39 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.1% 15/124 • Number of events 16 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.6% 31/247 • Number of events 32 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Dehydration	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypercreatininaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 10 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hyperglycaemia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.5% 13/124 • Number of events 22 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.9% 12/247 • Number of events 18 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.9% 11/124 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.6% 9/247 • Number of events 14 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.0% 5/124 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.7% 14/247 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypokalaemia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 8/247 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hypomagnesaemia	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.5% 8/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 8/247 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	17.9% 7/39 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.5% 13/124 • Number of events 17 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.9% 17/247 • Number of events 18 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Vitamin B12 deficiency	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Metabolism and nutrition disorders Vitamin D deficiency	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Arthralgia	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	17.9% 7/39 • Number of events 10 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.3% 18/247 • Number of events 21 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Back pain	23.1% 3/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.8% 5/39 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.3% 9/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.5% 21/247 • Number of events 21 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Joint swelling	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Muscle spasms	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 4/124 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.5% 11/247 • Number of events 13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.8% 6/124 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.3% 13/247 • Number of events 17 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hair follicle tumour benign	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanocytic naevus	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Dizziness	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	4.0% 5/124 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Dysgeusia	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Headache	15.4% 2/13 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.6% 7/124 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.9% 17/247 • Number of events 21 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Neuropathy peripheral	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 2/247 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Sensory loss	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Tremor	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Nervous system disorders Trigeminal neuralgia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Psychiatric disorders Anxiety	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Psychiatric disorders Depression	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Psychiatric disorders Insomnia	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.5% 8/124 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	3.2% 8/247 • Number of events 8 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Renal and urinary disorders Acute kidney injury	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Renal and urinary disorders Renal failure	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Cough	38.5% 5/13 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	20.0% 3/15 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	17.9% 7/39 • Number of events 10 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.3% 9/124 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.4% 33/247 • Number of events 37 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Dysphonia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 4/247 • Number of events 4 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	12.8% 5/39 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	16.1% 20/124 • Number of events 21 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.5% 26/247 • Number of events 27 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	13.3% 2/15 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.8% 7/247 • Number of events 9 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Productive cough	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.6% 2/124 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 6 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.6% 1/39 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Alopecia	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.40% 1/247 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Dry skin	15.4% 2/13 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.1% 2/39 • Number of events 2 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.0% 5/247 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Eczema	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.81% 1/124 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 7 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	9.7% 12/124 • Number of events 13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.7% 14/247 • Number of events 14 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Rash	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	7.7% 3/39 • Number of events 3 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	8.1% 10/124 • Number of events 14 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	5.3% 13/247 • Number of events 15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Skin and subcutaneous tissue disorders Rash erythematous	7.7% 1/13 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Vascular disorders Hypertension	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/15 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	10.3% 4/39 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	2.4% 3/124 • Number of events 10 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	1.2% 3/247 • Number of events 5 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.
Vascular disorders Venous thrombosis limb	0.00% 0/13 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	6.7% 1/15 • Number of events 1 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/39 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/124 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.	0.00% 0/247 • From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2 Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. HCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.

Additional Information

Medical Communications

Hoffman-La-Roche

Phone: 800 821-8590

Email: genentech@druginfo.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER